Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308660 | 1.00 | GPR119 (0.36) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3395739 | 0.85 | GRIK1 (0.37) | GPR119GRIK1GRIA2AR | |
| SCHEMBL3393330 | 0.85 | GRIK1 (0.41) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3392673 | 0.84 | GPR119 (0.39) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3303609 | 0.84 | GPR119 (0.39) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3298914 | 0.84 | AR (0.37) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3393487 | 0.84 | AR (0.37) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3394767 | 0.83 | GRIK1 (0.42) | GPR119TBK1GRIK1GRIA2AR | |
| SCHEMBL3303727 | 0.82 | GRIK1 (0.42) | GPR119GRIK1GRIA2ARKDM1A | |
| SCHEMBL3394535 | 0.82 | GRIK1 (0.42) | GPR119GRIK1GRIA2ARKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1368032-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003024453-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | GPR119 108/4885TBK1 1298/4885GRIK1 8/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | GPR119 108/4885TBK1 1298/4885GRIK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.